Loading organizations...
Key people at Excelestar Ventures.
Excelestar Ventures is a Boston, Massachusetts-based early-stage venture capital firm that invests primarily in medical technology and business-to-business software and hardware platforms. The firm focuses its capital deployment on Series A funding rounds and beyond, specifically targeting medical devices delivering therapy within addressable markets exceeding $1 billion. Additionally, the organization prioritizes deep technology investments and actively seeks to back companies led by women and diverse management teams that have achieved product-market fit and are preparing for commercialization. The firm guides its portfolio toward sustainable profitability with a long-term operational perspective, drawing on over fifteen years of institutional investment experience. Its historical portfolio includes investments in Conformal Medical, Diesel Labs, and Instylla, alongside successful exits such as Augmenix and nVision to Boston Scientific, and Altiostar Networks to Rakuten. Excelestar Ventures was founded by Tasneem Dohadwala.
Key people at Excelestar Ventures.
Excelestar Ventures is a global early-stage venture capital firm based in Andover, Massachusetts, focused on investing in technology, clean energy, healthcare, medical devices, B2B software/hardware platforms, and MedTech companies.[1][2][3] The firm's mission centers on helping portfolio companies achieve operational efficiencies, sustainable growth, and long-term profits while prioritizing underrepresented founders, particularly diverse and female-led teams.[2][3][4] Its investment philosophy emphasizes clear vision, disruptive value propositions, and industry diversity, as demonstrated by exits like Augmenix and nVision (acquired by Boston Scientific in 2018) and Altistar (acquired by Rakuten in 2021).[2] Excelestar impacts the startup ecosystem by providing hands-on support, mentoring women leaders, and backing resilient founders in tight funding markets, with a portfolio of 12 investments including recent ones like Brixton Biosciences and Instylla.[3]
Excelestar Ventures was founded by Tasneem Dohadwala, whose background spans traditional financial services, including sell-side roles at Lehman Brothers and Matrix Partners, complemented by a passion for advancing women in business and leadership.[2][3] Dohadwala, a Wellesley College and Harvard Business School graduate, established the firm to focus on early-stage ventures with strong teams and articulated strategies, evolving from medical technology successes to broader deep tech and diverse founder investments.[2][3] Key milestones include the 2018 Boston Scientific acquisitions of portfolio companies Augmenix and nVision, marking significant growth, and the 2021 Altistar exit to Rakuten, highlighting the firm's diversified tech focus; under her leadership, Excelestar was named one of Massachusetts' top 100 women-led businesses by The Boston Globe.[2][3] Dohadwala also serves as managing partner of the Golden Seeds Boston Chapter, reinforcing the firm's commitment to female entrepreneurs.[3]
Excelestar stands out in the VC landscape through these key strengths:
Excelestar rides the wave of deep tech and MedTech innovation, capitalizing on trends like advanced medical devices and B2B platforms amid rising demand for healthcare solutions and sustainable tech.[1][2] Timing aligns with a tight VC funding environment where consolidation favors resilient, diverse founders—Excelestar counters this by advocating equitable access and backing underrepresented teams, as noted in 2025 analyses of women accessing capital.[3] Market forces like acquisitions by giants (Boston Scientific, Rakuten) amplify its influence, while its clean energy and real estate holdings diversify beyond pure tech.[1] The firm shapes the ecosystem by mentoring female leaders, fostering industry diversity, and enabling operational scaling, positioning it as a bridge for startups expanding global presence.[2][3][4]
Excelestar Ventures is poised for expanded influence in MedTech and deep tech, with trends like AI-driven healthcare and alternative funding channels favoring its diversity-first, hands-on approach.[2][3] Upcoming focuses may include more Series B follow-ons and women-led ventures, building on 2024 investments amid resilient founder momentum.[3] As VC markets evolve, its track record and network could drive additional high-profile exits, amplifying underrepresented voices and solidifying its role in sustainable startup growth—echoing its core mission of turning visionary teams into industry leaders.[2][3]
Excelestar Ventures has 4 tracked investments across 3 companies. The latest tracked deal is $30.0M Other Equity in Instylla in August 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 16, 2023 | Instylla | $30.0M Other Equity | Henry Chen | AMED Ventures, Ascension Ventures, Catalyst Health Ventures, Amarpreet Sawhney, Sparta Group |
| Aug 1, 2023 | Instylla | $30.0M Series C | Delos Capital | Golden Seeds, AMED Ventures, Ascension Ventures, Catalyst Health Ventures, Incept, Sparta Group |
| Feb 24, 2015 | Altiostar Networks | $20.0M Other Equity | — | Cisco |
| Jul 23, 2014 | SpaceOAR | $10.8M Series D | — | Catalyst Health Ventures, CHV II, Sparta Group |
